KINIKSA PHARMACEUTICALS INTE (KNSA) Forecast, Price Target & Analyst Ratings
NASDAQ:KNSA • GB00BRXB0C07
46.02 USD
-1.25 (-2.64%)
At close: Mar 5, 2026
46.02 USD
0 (0%)
After Hours: 3/5/2026, 8:03:08 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KINIKSA PHARMACEUTICALS INTE (KNSA).
Forecast Snapshot
Consensus Price Target
$56.99
+ 23.84% Upside
Next Earnings Forecast
Release DateApr 21, 2026
PeriodQ4 / 2025
EPS Estimate$0.38
Revenue Estimate198.91M
ChartMill Buy Consensus
86.15%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$56.99
Upside
+ 23.84%
From current price of $46.02 to mean target of $56.99, Based on 13 analyst forecasts
Low
$50.50
Median
$57.63
High
$65.10
Price Target Revisions
1 Month
1.59%
3 Months
3.47%
Price Target Summary
13 analysts have analysed KNSA and the average price target is 56.99 USD. This implies a price increase of 23.84% is expected in the next year compared to the current price of 46.02.
The average price target has been revised upward by 3.47% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.15%
KNSA was analyzed by 13 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about KNSA.
In the previous month the buy percentage consensus was at a similar level.
KNSA was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-25 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-02-25 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-19 | Canaccord Genuity | Initiate | Buy |
| 2026-01-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-10-29 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-10-17 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-09-29 | TD Cowen | Initiate | Buy |
| 2025-09-25 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-29 | Jefferies | Maintains | Buy -> Buy |
| 2025-07-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-29 | Jefferies | Maintains | Buy -> Buy |
| 2025-04-16 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-03-13 | Citigroup | Initiate | Buy |
| 2024-11-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-10-30 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-09-13 | Jefferies | Initiate | Buy |
| 2024-07-23 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-05-03 | Wells Fargo | Initiate | Overweight |
| 2024-05-01 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-04-24 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-01-02 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-07-26 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-03-09 | JP Morgan | Maintains | Overweight |
| 2021-12-29 | B of A Securities | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 21, 2026
PeriodQ4 / 2025
EPS Estimate$0.38
Revenue Estimate198.91M
Revenue Q2Q62.33%
EPS Q2Q418.22%
Number of Analysts10
Next Earnings Revisions
Revenue (1 Month)
1.06%
Revenue (3 Months)
1.29%
EPS (1 Month)
-1.66%
EPS (3 Months)
-8.34%
Next Earnings Summary
KNSA is expected to report earnings on 4/21/2026. The consensus EPS estimate for the next earnings is 0.38 USD and the consensus revenue estimate is 198.91M USD.
The next earnings revenue estimate has been revised upward by 1.29% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 220.18M 471.24% | 270.259M 22.74% | 423.239M 56.60% | 689.83M 62.99% | 919.51M 33.30% | 1.077B 17.13% | 1.19B 10.49% | 1.29B 8.40% | 1.392B 7.91% | 1.518B 9.05% | 1.806B 18.97% | 1.931B 6.92% | |
| EBITDA YoY % growth | 12.173M 107.89% | -22.855M -287.75% | -43.921M -92.17% | 97.71M 322.47% | 195.6M 100.18% | 324.57M 65.94% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 9.773M 106.24% | -25.196M -357.81% | -45.616M -81.04% | 90.61M 298.64% | 168.42M 85.87% | 247.18M 46.76% | 214.26M -13.32% | 291.89M 36.23% | 433.87M 48.64% | 643.96M 48.42% | 828.24M 28.62% | 939.42M 13.42% | |
| Operating Margin | 4.44% | -9.32% | -10.78% | 13.14% | 18.32% | 22.95% | 18.01% | 22.63% | 31.17% | 42.42% | 45.86% | 48.65% | |
| EPS YoY % growth | 2.59 212.61% | 0.18 -93.05% | -0.61 -438.89% | 0.94 254.67% | 1.60 69.07% | 2.34 46.60% | 2.96 26.50% | 3.00 1.38% | 3.61 20.41% | 4.26 18.08% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.38 418.22% | 0.35 213.72% | 0.41 79.61% | 0.45 96.24% | 0.44 15.75% |
| Revenue Q2Q % growth | 198.91M 62.33% | 216.3M 56.98% | 219.27M 39.84% | 229.84M 27.09% | 238.37M 19.84% |
| EBITDA Q2Q % growth | 37.427M 312.61% | 31.83M 133.75% | 36.02M 72.65% | 42.556M 69.49% | N/A |
| EBIT Q2Q % growth | 32.141M 266.54% | 35.038M 164.00% | 36.355M 80.33% | 39.659M 65.10% | 36.873M 14.72% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
80.02%
EPS Next 5 Year
47.22%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
35.52%
Revenue Next 5 Year
24.42%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
139.15%
EBIT Next 5 Year
N/A
KINIKSA PHARMACEUTICALS INTE / KNSA Forecast FAQ
What do analysts expect the price target to be for KINIKSA PHARMACEUTICALS INTE (KNSA)?
13 analysts have analysed KNSA and the average price target is 56.99 USD. This implies a price increase of 23.84% is expected in the next year compared to the current price of 46.02.
Can you provide the upcoming earnings date for KINIKSA PHARMACEUTICALS INTE?
KINIKSA PHARMACEUTICALS INTE (KNSA) will report earnings on 2026-04-21.
Can you provide the consensus estimates for KINIKSA PHARMACEUTICALS INTE next earnings?
The consensus EPS estimate for the next earnings of KINIKSA PHARMACEUTICALS INTE (KNSA) is 0.38 USD and the consensus revenue estimate is 198.91M USD.
What is the expected long term growth rate for KINIKSA PHARMACEUTICALS INTE (KNSA)?
The expected long term growth rate for KINIKSA PHARMACEUTICALS INTE (KNSA) is 35.52%.